Novo Nordisk A/S is planning to separate its healthcare businesses from its enzymes business to enable it to participate in industry consolidation, as the company's board has finally bowed to shareholder pressure to make the company's businesses more transparent and attractive to potential partners.

The restructuring also could see it seeking a listing for its wholly owned U.S. subsidiary, ZymoGenetics Inc.